Wednesday, 17 June 2020

Menstrual Cup Market 2020 Global Overview, Regional Analysis, Size, Share And Forecast To 2025

Menstrual Cup Market Summary
Global Menstrual Cup market Size is anticipated to reach USD 1514.01 million by 2023, as per a new detailed report by Market Research Future (MRFR). It is expected to exhibit a 3.50% CAGR during the assessment period (2018-2023). The rise in the women populace coupled with high costs of sanitary pads and tampons are expected to drive Menstrual Cup market growth over the forecast period. Demand for eco-friendly feminine hygiene products can bode well for the market
Menstrual Cup are an eco-friendly alternative to tampons or sanitary napkins derived from medical-grade silicone. The rise of the women workforce coupled with the female gender representing nearly half of the global population are factors expected to spur the Menstrual Cup market growth. In addition, the products can prevent leakage of menstrual fluids with no reported adverse effects.
Menstrual Cup Market Report Overview
This report allows the user to gain a deeper understanding of the ongoing events and trends in the global market for Menstrual Cup. By correlating the historical data with key market dynamics, our analysts were able to make highly accurate projections in the report. MRFR’s report includes a thorough segmental analysis of the global Menstrual Cup market segmented by product type, test type, end-user, and region with astute insights. This report has been prepared to assist industry participants in making informed decisions on growth strategies and operation management. Users will also come across drivers, trends, opportunities, and restraints which are likely to influence the growth of the Menstrual Cup market during the assessment period.
Menstrual Cup Market Players Covered
Me Luna, LadyCup, Ruby Life Ltd., Lunette, Irisana S.A., The Keeper, Inc., Vcup, Anigan, FemCap, Inc., and Diva International Inc., are prominent players in the Menstrual Cup market. These companies have turned to online channels and digital marketing to create their niche. Online channels offer privacy to users with consumers choosing to buy sanitary products at their own discretion.

Menstrual Cup Market Segment Overview

By product, the Menstrual Cup market has been segmented into reusable and disposable Menstrual Cup. Reusable cups will dominate the market by accounting for a large market share by 2023. This can be attributed owing to reusability cycle of these cups ranging from 1 to 5 years depending on the brand. By type, the market is segmented into hollow, pointy, flat, and round. The round segment accounted for 43% market share due to the flexibility in the design of these products.
By distribution channel, the market is segmented into online stores, retail outlets, and others. The online store channel segment accounted for 62% market share owing to penetration of e-commerce stores and changing buying patterns of consumers.
The segments and sub-segments covered in the report are analyzed under four major regions –Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA), with respective country-level market sizing. For the scope of research, the standard definition of the product/ service “Menstrual Cup” is included in the report. The report discusses and interprets the current and future opportunities of the industry by delivering an unbiased growth assessment.
The report offers comprehensive profiles on these market players and assesses their current standing in the Menstrual Cup market. Company history coupled with annual turnover, segmental share, SWOT analysis, growth strategies, new product launches, M&A activities, and latest R&D initiatives are outlined in the report.
Menstrual Cup Market Research Methodology
Market Research Future (MRFR) uses a combination of primary and secondary research to compile market reports. Primary data is accumulated from interviewing industry stalwarts, and secondary research is collated by studying white papers and annual reports of leading players. Our analysts use top-down and bottom-up approaches to validate the findings of the report. The report comprises news, current trends, and future prospects related to the market, all of which can provide a thorough understanding of the market to clients. Industry leaders can make accurate business decisions based on our insights.
Posted by at No comments:

Ureteral Stents Market Overview With Detailed Analysis, Competitive Landscape, Forecast To 2025

Market Scenario

Ureteral Stents Market Growth is expected to register 6.6% CAGR during the forecast period of 2019 to 2025, with a market value of USD 302.5 Million in 2018.
A ureteral stent is a thin tube inserted into the ureter to prevent or treat an obstruction of the urine flow from the kidney. The length of the stents used in adult patients varies between 24 and 30 cm.
The global ureteral stents market is driven by factors such as the rising prevalence of kidney diseases and the increasing number of kidney transplants.
Additionally, the technological advancements in ureteral stents and the rising adoption of minimally invasive surgeries are anticipated to fuel the market growth.
For instance, as per the Global Observatory on Donation and Transplantation, in 2016, 89,823 kidney transplants were done globally. Thus, the rising number of kidney transplants fueling the growth of the market.
Moreover, major companies in the market are involved in strategic acquisitions, collaborations, mergers, and new launches to sustain their position in the market.
 For instance, in February 2017, Cook Medical launched Universa, a soft ureteral stent set, in its streamline percutaneous urinary drainage product line. This helped strengthen its ureteral stents product portfolio.
Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/1389
Segmentation
The global ureteral stents market has been segmented based on type, material, treatment, end users, and region.
The global market, based on type, has been bifurcated into double pigtail ureteral stent and others.
The double pigtail ureteral stent segment is expected to hold a significant share of the market due growing use of double pigtail ureteral stents as it provides a safe and effective method of ensuring urinary drainage.
Based on material, the global market is segmented into metallic stents, polymers stents, and others. The polymers stents segment is expected to hold a major share of the market due to growing use of bioabsorbable stents and technological improvement in ureteral stents.
The market, based on treatment, has been divided into kidney stones, kidney transplants, and others.
The kidney stones treatment is expected to hold a major share in the market due to the increasing prevalence of kidney stones. For example, according to Urology Annals, in 2018, worldwide, prevalence of kidney stones is 7% in adults, which will increase with recurrence rate of 30% within ten years. The incidence of kidney stones is growing globally with an estimated prevalence ranging up to 15%. During their lifetime, approximately 7% of women and 13% of men will develop a kidney stone.
Based on end user, the market is segmented into hospitals, nephrological centers, and ambulatory surgical centers. The hospitals segment is expected to hold a major share in the market due availability of facilities for kidney transplant procedures and availability of expertise in the hospital.
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The ureteral stents market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European ureteral stents market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
 The ureteral stents market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The ureteral stents market in the Middle East & Africa has been divided into the Middle East and Africa.
Key Players
The Key Players operating in the Global Ureteral Stents Market are Boston Scientific (US), Cook Medical (US), C.R. Bard (US), B. BRAUN (Germany), Olympus (Japan), Coloplast (Denmark), Allium Medical (Israel), Teleflex Incorporated (US), Biomerics (Italy), Medline industries inc. (US), Merit Medical Systems, Inc. (US), and BrightWater Medical (US).
Regional Market Summary
The market in the Americas is expected to dominate the ureteral stents market due to the growing early product commercialization in the region, growing use of ureteral stents and the involvement of key companies are driving the growth of this market. The increasing incidence of kidney diseases in the US and Canada is expected to drive the market growth.
For instance, as per the statement of the National Center for Biotechnology Information, in the US, kidney stone affects 1 in 11 individuals, and it is estimated that 600,000 Americans suffer from kidney stones each year.
The market in the Asia-Pacific is expected to hold the second-largest share of the ureteral stents market due to the growing prevalence of kidney diseases, increasing geriatric population, and the increasing awareness about advanced medical devices in the region.
For example, as per the statement of the National Center for Biotechnology Information, in India about 12% of the population is expected to have urinary stones, of which 50% may end up with loss of kidney functions.
The market in Europe is projected to have a steady growth rate during the forecast period owing to the increasing preference for minimally invasive procedures and improved insurance and reimbursement policies.
The market in the Middle East & Africa is projected to account for the least share of the market due to low per capita disposable income in the region.
Posted by at No comments:

DPT vaccine Market 2020 Global Overview, Regional Analysis, Size, Share And Forecast To 2027

Market Synopsis of DPT vaccine Market:

Globally the market for DPT vaccine is increasing rapidly. The major factor that derives the growth of DPT vaccine is the increasing deaths in children due to pertussis. Furthermore increasing awareness for DPT vaccines is increasing the growth of DPT vaccine market. Globally the Diphtheria, Pertussis, and Tetanus Vaccine Market Share is expected to grow at the rate of about XX% CAGR from 2016 to 2027.

Study Objectives of DPT vaccine Market:

  • To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the DPT vaccine market  
  • To provide insights about factors affecting the market growth
  • To analyze the DPT vaccine market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
  • To provide country level analysis of the market with respect to the current market size and future prospective
  • To provide country level analysis of the market for segments by type, by applications and its sub-segments.
  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global
Key Players for DPT vaccine Market:                                                            
Some of the key players in this market are: Merck & Co., Inc (U.S), Sanofi (France), GSK (U.S), Lanzhou Institute of Biological Products (China), wyeth (U.S), Chiron Pharmaceutical Pvt Ltd (India) and many others.
Segments:
Global DPT vaccine market has been segmented on the basis of type which comprises of DPaT, DTwP and Tdap. On the basis of applications include diphtheria, pertussis and tetanus.
Regional Analysis of DPT vaccine Market:                                                             
Globally North America is the largest market for DPT vaccine. The North American market for DPT vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. This is due to increasing number of deaths of children in the country. Europe is the second-largest market for DPT vaccine which is expected to grow at a CAGR of XX%. Furthermore Asia pacific market is expected to be the growing market for DPT vaccine market.
The report for Global DPT vaccine Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the segments and regions of the different market.
Posted by at No comments:

Biosimilars Market By Key Vendors, Regions, Trends With Industry Study & Forecast To 2025

Biosimilars Market Scenario

Biosimilars Market Growth is expected to register a CAGR of 7.5% during the forecast period of 2019 to 2025, with a market value of USD 13,460 Million in 2018.
A biosimilar is a biologic medical product highly similar to another already approved biological medicine. Biosimilars are approved according to the same standards of pharmaceutical quality, safety, and efficacy that apply to all biological medicines. The global biosimilars market is driven by factors such as rising demand for biosimilars due to their cost-effectiveness and growing prevalence of chronic diseases. Additionally, rising pressure to reduce healthcare expenditure coupled with patent expiry of various blockbuster drugs and the increasing number of biosimilar drug approvals by the FDA is anticipated to fuel the market growth.
 For instance, according to the biosimilars update report by Amgen in 2019, As of January 2019, the US Food and Drug Administration (FDA) approved 17 biosimilars, out of which 7 products launched in 4 therapeutic areas. On the other hand, patient safety and medical efficacy are projected to hamper the growth of the market during the assessment period. Moreover, major companies in the market are involved in strategic acquisitions, collaborations, and mergers to sustain their position in the market.
For instance, in October 2018, Sandoz, a Novartis division received the US Food and Drug Administration (FDA) approval for its biosimilar, HyrimozTM (adalimumab-adaz) for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PSA),  juvenile idiopathic arthritis (JIA) in patients four years of age and older, ulcerative colitis (UC), ankylosing spondylitis (AS), adult Crohn's disease (CD), and plaque psoriasis (Ps)
Biosimilars Market Segmentation
Global Biosimilars Market has been segmented based on product, applications, end users, and region.
The market, based on product, has been bifurcated into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides.
The recombinant non-glycosylated proteins are further divided into human growth hormone (RHGH), granulocyte colony-stimulating factor (filgrastim), insulin, and interferons. Similarly, the recombinant glycosylated proteins segment is further bifurcated into erythropoietin (EPO), monoclonal antibodies (MABS), and follitropin. The recombinant peptides segment has been subdivided into glucagon and calcitonin
The recombinant non-glycosylated proteins segment is expected to hold a major share in the market due to an increase in the number of incidences of chronic diseases, diabetes also growth hormone deficiency-related disorders. Thus, the therapeutic use of recombinant non-glycosylated proteins is broadening as their increased availability and lowered price.  
For example, according to the International Diabetes Federation (IDF), in 2017, approximately 425 million adults aged between 20 to 79 years suffered from diabetes, and this number is expected to rise to 629 million by 2045.
On the basis of applications, the global biosimilars market has been divided into oncology, chronic diseases, autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and others. Blood disorders segment is expected to grow with high growth rate due to increased prevalence of blood disorders and adoption of biosimilars as its low cost in comparison to biologics reduces the treatment cost.
For example, according to the Centers for Disease Control and Prevention in the US, hemophilia A affects 1 in 5,000 male births, and about 400 babies are born with hemophilia A each year.
Based on end user, the market has been divided into hospitals and clinics is expected to hold the largest share in the market as easy availability for treatment with expert faculties.
Based on region, the global biosimilars market has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The biosimilars market in the Americas has further been segmented into North America and Latin America; the North American market has been further divided into the US and Canada.
The European biosimilars market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as France, the UK, Germany, Italy, Spain, and the rest of Western Europe. The biosimilars market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The biosimilars market in the Middle East & Africa has been divided into the Middle East and Africa.
Biosimilars Market Key Players
The key players in the Global Biosimilars Market are Pfizer (US), Sandoz International (Germany), Teva Pharmaceuticals (Israel), Amgen, Inc. (US), Biocon (India), Dr. Reddy’s Laboratories (India), Celltrion (South Korea), Samsung Biologics (South Korea), Eli Lily & Company (US), Hospira Inc.(US), Actavis, Inc.(US), Cipla Ltd (India), Stada Arzneimittel AG (Germany), and Mylan, Inc.(US).
Regional Market Summary
The market in Europe is expected to dominate the global biosimilars market due to the increasing biosimilar product approvals and the emergence of new market participants in the region. The growing prevalence of chronic diseases in the US and Canada is expected to drive the market growth. Furthermore, there has been an increase in the expenditure in research by healthcare bodies; this is expected to fuel the growth of the market in this region. For example, according to Amgen, in 2019, Europe has an advanced biosimilar market, with 53 approved biosimilar products. The market in Asia-Pacific expected to show a considerable amount of growth. This can be attributed to the patent expiry of biologic products, introduction of new biosimilars, adoption of biosimilars to reduce the treatment cost, and the involvement of key companies. For instance, according to the National Center for Biotechnology Information, in 2019, Many key biologics are scheduled to lose their patent by the year 2020, which will provide the opportunity to other biopharmaceutical companies to develop similar biologics. Already there are more than 100 Indian biopharmaceutical companies are engaged in manufacturing and marketing of biosimilar. The market in Americas is projected to have a steady growth rate during the forecast period owing to an increase in chronic diseases and well-developed healthcare system. The market in the Middle East & Africa is projected to account for the least share of the global market due to low disposable income in the region.
Posted by at No comments:

Erectile Dysfunction Drugs Market 2020 Global Dynamics, Trends, Opportunities, Drivers, Challenges And Influence Factors Shared In A Latest Report

Erectile Dysfunction Drugs Market Scenario

Global erectile dysfunction drugs market is expected to register a CAGR of 3.5% during the forecast period of 2019 to 2025 with a market value of USD 2930 million in 2025.
Erectile dysfunction (ED) is defined as persistent difficulty achieving and maintaining an erection sufficient to have sex.
The global erectile dysfunction drugs market demand is driven by factors such as increasing number of men suffering from this disorder, rising geriatric population and patent expiry of number of blockbuster drugs.
Additionally, increasing manufactures of generic drugs coupled with rising adoption of a sedentary lifestyle along with the associated stress is anticipated to fuel the market growth.
For instance, according to The Massachusetts Male Aging Study (MMAS), worldwide incidence of erectile dysfunction will increase from 152 million men in 1995 to 322 million men by the year 2025.
On the other hand, poor patient adherence to erectile dysfunction drugs is projected to hamper the growth of the market during the assessment period.
Moreover, major companies in the market are involved in strategic acquisitions, collaborations, mergers, and new product launch to sustain their position in the market.
For instance, in December 2017, Teva Pharmaceutical Industries Ltd. announces exclusive launch of a generic version viagra tablets in the US.
Erectile Dysfunction Drugs Market Segmentation
The global erectile dysfunction drugs market has been segmented based on and region.
The market, based on drug, has been bifurcated into viagra (sildenafil citrate), cialis (tadalafil), staxyn/levitra (vardenafil), stendra/spedra (avanafil), zydena (udenafil), vitaros (alprostadil cream), and others. The market, on the basis of end user, has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Based on drug, viagra segment is expected to hold a major share in the market as it is the first Food and Drug Administration (FDA) approved oral treatment for erectile dysfunction. In 1998, Pfizer introduced viagra which is dominating the erectile dysfunction market. Cialis segment is expected to be the fastest growing segment as cialis provides an erection over a longer period than viagra, cialis lasts up to 18 hours, while viagra only lasts for about 4 to 6 hours.
On the basis of end user retail pharmacy segment is expected to be the largest segment as it is available easily in the retail stores. The hospital pharmacy segment is expected to be the fastest growing segment as increasing pool of patient due to increasing awareness and patient education.
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The erectile dysfunction drugs market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European erectile dysfunction drugs market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The erectile dysfunction drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The erectile dysfunction drugs market in the Middle East & Africa has been divided into the Middle East and Africa.
Key Players
The key players in the global erectile dysfunction drugs market are Pfizer, Inc., Apricus Biosciences Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltd., Dong-A Pharmaceutical Co. Ltd., Eli Lilly and Company, Meda Pharmaceuticals, Inc., S.K. Chemicals Co. Ltd., Vivus, Inc., Teva Pharmaceutical Industries Ltd.
Regional Market Summary
The market in the Americas is expected to dominate the global erectile dysfunction drugs market due to the rising prevalence of erectile dysfunction and increasing awareness & patient education in the region. High cases of erectile dysfunction in the US and Canada is expected to drive the market growth. For example, as per the survey, overall prevalence of erectile dysfunction in men aged more than 20 years was 18.4% suggesting that erectile dysfunction affects 18 million men in the US. Furthermore, increasing expenses in research by healthcare bodies engaged in research of novel drugs is expected to fuel the growth of the market in this region. The market in Europe showed a considerable amount of growth. This can be attributed to the increasing adoption of a sedentary lifestyle along with the associated stress in the European region. The market in Asia-Pacific is projected to have a fastest growth rate during the forecast period owing to the increasing geriatric population and rising availability of generic drugs. For example, according to The United Nations Population Fund, by 2050, 1 in 4 people in Asia and the Pacific will be over 60 years old. The population of older people (aged over 60) in the region will triple between 2010 and 2050 and will reach close to 1.3 billion people. The incidences of erectile dysfunction increase with the growing age hence Asia-Pacific market will grow fast in the forecasted period. The market in the Middle East & Africa is projected to account for the least share of the global market due to low awareness and patient education in the region.
Posted by at No comments:

Global Invisible Orthodontics Market 2020 Insights Business Opportunities, Current Trends And Restraints Forecast 2025

Market Forecast
Invisible Orthodontics Market share reached a value of USD 2598.8 Million in 2018 and is expected to register a CAGR of 13.99% during the assessment period of 2019 to 2025.
Global Invisible Orthodontics Market Analysis By Product Type (Clear Aligners, Braces, Clear Retainers), Age Group (Below 15, 16-35, Above 35), Application (Excessive Spacing, Crowding, Malocclusion, Others), Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast to 2025
Market Synopsis
With the evolving technological advancements in the dental field, the area of invisible orthodontics has gained extensive popularity. Bracket-less aligners, clear retainers, and invisible braces some of the examples of cutting-edge technologies which have been launched in recent years. The high incidence rate of dental diseases in the developing countries and the rising inclination towards the correction of teeth deformities are likely to fuel the growth of the invisible orthodontics market across the globe. For instance, in Brazil, approximately 1.4 million new orthodontic cases are reported every year. Therefore, the key players involved in the invisible orthodontics market are vigorously focusing on product approvals to expand their customer base and brace their position in the market.
Moreover, the field of dentistry is evolving day by day. Public, as well as private organizations, are focusing on catering to the changing needs of the customers in terms of providing demos, conducting campaigns and dental check-ups. Thus, the employment of such strategies will promise the growth of the invisible orthodontics substantially.
Market Influencer
Increasing support by regulatory authorities to the private and public companies, in terms of investment and product approvals, acts as a significant factor that contributes substantially to the growth of the invisible orthodontics market in the longer run.
Market Drivers
  • The increasing prevalence of dental diseases pushes the need for newer treatment options, indirectly fueling the growth of the invisible orthodontics market globally. For instance, 90% of Australians are experiencing tooth decay. Such a high occurrence rate pushes the patients to choose newer techniques and prevention methods, thus fueling the growth of the invisible orthodontics market.
  • Several established players, such as Align Technology, Inc., and Dentsply Sirona are actively involved in getting approvals from regulatory authorities for their products in the invisible orthodontics market. For instance, in March 2017, Align Technology, Inc. launched the Invisalign Teen with mandibular advancement, the first clear aligner solution for Class II correction in growing tween and teen patients. This elucidates the impression that such new approvals are sure to drive the growth of the invisible orthodontics market in the near future.
  • Partnerships and collaborations between key players and local players
  • Increasing technological improvements in the orthodontics industry
  • High investment in research and development for the development of efficient products
  • Growing awareness created by dental professionals and key players about the benefits of clear aligners among the patients
Market Restraints
  • Limitations of invisible orthodontic products. Products such as clear aligners require long treatment time, which is why some of the patients do not prefer these products. In addition, poor compliance of patients with the dentists’ instructions leads to other complications of using these aligners. This results in a decreased target audience which would be utilizing such products, indirectly curbing the growth of the market.
  • Grey market for dental distribution, in terms of illegal selling of products of low quality at a cheaper price
Segmentation
By Product Type
  • Clear Aligners: The clear aligners segment is further segmented into hard, medium, and soft. The hard aligners sub-segment held a market value of an approximate of USD 1,394 million in 2018. The clear aligners segment held the largest share in 2018 due to a number of product launches by key companies such as Align Technology, Inc., Danaher, and others.
  • Braces: This segment has been further divided into ceramic braces and lingual braces. The braces segment is expected to be the fastest-growing during the forecast period owing to the increased awareness about the benefits created by key companies by conducting campaigns and dental check-ups.
  • Clear Retainers: A clear retainer is molded perfectly to fit the new position of the teeth.
By Age Group
  • Below 15: Various companies are getting approvals of their products for adolescents. In March 2017, Align Technology, Inc. launched the Invisalign Teen clear aligner for teenagers. Such increasing initiatives by prominent players for the below 15 age group fuels the growth of this segment.
  • 16-35: People in this age group are highly affected by dental disorders, including bite issues, due to change in lifestyle in recent years. This huge patient pool acts as a perfect target audience for prominent players to develop their products. Thus, the16-35 segment is likely to be the fastest-growing segment during the forecast period.
  • Above 35: The increasing middle-aged and geriatric pool of population suffering from dental caries, weakening of gums, abnormal eruptions in the teeth, among others, are the key factors for the growth of the above 35 segment. The benefits of clear braces are becoming palpable as a growing number of adult patients are now pursuing dental care.
By Application
  • Excessive Spacing: Spacing may prevent the teeth from functioning properly and may also result in gum problems due to the lack of protection provided by the teeth. Therefore, companies are coming up with products for corrective measures and conducting workshops and campaigns to create awareness. Thus, this segment held a majority share in 2018.
  • Crowding: Crowding can either be the result of several other orthodontic problems, such as impacted teeth, and teeth that do not fall out naturally, among others.
  • Malocclusion: The market, based on malocclusion, has been segmented into open bite, deep bite, and crossbite. The malocclusion segment is expected to be the fastest-growing segment during the assessment period owing to the increasing number of patients suffering from crossbites and open bites. Moreover, companies such as Align Technology, Inc. has a portfolio of products which are primarily used for the treatment of malocclusion. Thus, such factors are fueling the growth of this segment.
  • Abnormal Eruptions: Abnormal eruption occurs when a tooth emerges through the gum in the wrong place.
  • Others: Other applications of invisible orthodontic products are for correcting overjets, underbites, and others.
By Region
  • Americas: Americas was the largest regional market in 2018, owing to the continuous activities such as acquisitions, and partnerships employed by prominent players in the major countries in America. For instance, in March 2018, Dentsply Sirona (US) announced the acquisition of OraMetrix (US), a leading industry provider of innovative 3D technology solutions in the field of orthodontics. With this, the company aims to strengthen its position in the American invisible orthodontics market.
  • Europe: The European region holds the second largest share as there is increasing support from regulatory authorities, as well as ample of distributors in the European countries. For instance, in December 2017, Institut Straumann AG (Switzerland) acquired Same Day Solutions (SDS), a dental distribution company in Portugal. This acquisition provided Straumann access to SDS’ customers, which added the sales power and has been helping in supporting the company’s operations in Portugal.
  • Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global invisible orthodontics market. Direct marketing initiatives by the manufacturers to consumers are playing a substantial role in increasing the target audience and thus increasing the market size in this region. Also, strategic joint ventures by key players are contributing to the growth of the market. For instance, in January 2019, Institut Straumann AG, a company based in Switzerland, entered into a strategic partnership with a Chinese company, Tianjin ZhengLi Technology Company Limited. With this, Institut Straumann AG obtained exclusive distribution rights in China for its clear aligners, and the company aims to leverage its strong marketing and distribution capabilities to penetrate the highly attractive Chinese market. Thus, such strategies are likely to fuel the growth of the Asia-Pacific invisible orthodontics market.
  • Middle East & Africa: The smallest market due to limited healthcare infrastructure. But, in the last few years, top companies operating in the invisible orthodontics market are involved in acquiring different local distributors in the Arabian region to gain foothold in the local markets.
Key Players
  • 3M (US)
  • Align Technology, Inc. (US)
  • Clarus Company (US)
  • ClearPath Healthcare Services (US)
  • Danaher Corporation (US)
  • Dentsply Sirona (US)
  • DynaFlex (US)
  • Henry Schein, Inc. (US)
  • Institut Straumann AG (Switzerland)
  • Ormco (US)
Posted by at No comments:

Biosimulation Market 2020 Covers Global Industry Share, Size, Gross Margin, Future Trends, Demand, Business Insight By Leading Key Players Forecast Till 2025

According to MRFR analysis, Biosimulation Market is expected to register a CAGR of 15.9% during the forecast period of 2019 to 2025 and is likely to be valued at USD 4.4 Billion by 2025.  
Biosimulation is a tool used for the prediction of the outcomes of existing clinical trials associated with innovation and new drug development.
The growth of the Global Biosimulation Technology Market size is determined by numerous factors such as the growing adoption of biosimulation software by regulatory bodies, increasing healthcare expenditure, increasing use of pharmacokinetic & pharmacodynamic modeling in pre-clinical development and rising need to reduce the drug development costs. However, lack of standardization in biosimulation methodology and lack of trained professionals for monitoring biosimulation software are likely to hamper the growth of the global biosimulation market during the forecast period.  
Several market players currently dominate the Global Biosimulation Market. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in September 2019, Certara Inc. launched version 8.2 of Phoenix, the most advanced and widely used validated software for PK, PD, and toxicokinetic modeling and simulation worldwide.
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
Americas has been segmented into North America and Latin America, with the North American market being divided into the US and Canada. The Americas is projected to hold the largest market share owing to the increasing R&D spending by pharmaceutical and biotechnology companies in the region and growing number of clinical trials & drug development practices.  
The European biosimulation market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The biosimulation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Rising geriatric population and the presence of a large patient pool, are the key factors responsible for the fastest growth of the market in Asia-Pacific. The biosimulation market in the Middle East & Africa has been divided into the Middle East and Africa.
Segmentation
The Global Biosimulation Market has been segmented based on product, application, delivery model and end users.
The market, based on product, has been divided into software and services. The software segment is further segmented into PK/PD (pharmacokinetic/pharmacodynamic) modeling and simulation software, molecular modeling and simulation software, PBPK (physiologically based pharmacokinetic) modeling and simulation software, toxicity prediction software, trial design software, and others. The services segment is further segmented into in-house services and contract services. The software segment is likely to hold the maximum market share in the global biosimulation market owing to growing adoption of biosimulation software by pharmaceutical and research organizations and the increasing R&D investment for pharmaceutical research.
The global biosimulation market based on the application has been segregated into drug development, drug discovery, and others. The drug development segment is expected to hold a larger share of the market share owing to the rising adoption of biosimulation tool for the drug development process.
The delivery model segment of the market is divided into subscription models and ownership models.
Based on end users, the global biosimulation market has been segmented into pharmaceutical and biotechnology companies, contract research organizations, research institutes, regulatory authorities, and others. Rising adoption of inorganic growth strategies by different biosimulation service providers is likely to boost the adoption of biosimulation solutions in the pharmaceuticals and biotechnology companies.
Key Players
Some of the Key Players in the Global Biosimulation Market are Dassault Systèmes (France), Certara USA, Inc. (US), Simulation Plus (US), Schrödinger (US), Chemical Computing Group (Canada), Physiomics (UK), In Silico Biosciences (US), Advanced Chemistry Development, Inc. (Canada), Genedata AG (Switzerland), Nuventra Pharma (US), Evidera (US), Leadinvent Technologies (India), LeadScope, Inc. (US), Rosa (US) and INOSIM Software GmbH (Germany).
Posted by at No comments:
Subscribe to: Posts (Atom)